Arcturus Therapeutics Holdings Stock Gross Profit

ARCT Stock

USD 16.91 0.16 0.94%

Arcturus Therapeutics Holdings fundamentals help investors to digest information that contributes to Arcturus Therapeutics' financial success or failures. It also enables traders to predict the movement of Arcturus Stock. The fundamental analysis module provides a way to measure Arcturus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcturus Therapeutics stock.

	Last Reported	Projected for Next Year
Gross Profit	154.8 M	162.5 M
Gross Profit Margin	0.98	1.03

Gross Profit is likely to gain to about 162.5 M in 2024. Gross Profit Margin is likely to gain to 1.03 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arcturus Therapeutics Holdings Company Gross Profit Analysis

Arcturus Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Arcturus Therapeutics Gross Profit

62.95 M

Most of Arcturus Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcturus Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arcturus Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Arcturus Therapeutics is extremely important. It helps to project a fair market value of Arcturus Stock properly, considering its historical fundamentals such as Gross Profit. Since Arcturus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcturus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcturus Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Investments	Current Deferred Revenue	Short Long Term Debt	Net Invested Capital	Net Working Capital	Long Term Debt	Long Term Debt Total	Capital Stock	Deferred Long Term Liab
Total Assets		0.98	-0.97	-0.91	0.84	0.61	0.92	1.0	-0.24	0.54	0.95	0.77	0.96	-0.63	0.88	0.78	0.96	0.96	0.84	0.84	-0.87	0.57
Total Stockholder Equity	0.98		-0.98	-0.82	0.81	0.56	0.83	0.98	-0.24	0.45	0.98	0.68	0.92	-0.58	0.8	0.69	0.97	0.97	0.74	0.74	-0.81	0.43
Net Debt	-0.97	-0.98		0.79	-0.91	-0.44	-0.84	-0.98	0.25	-0.51	-0.97	-0.6	-0.9	0.6	-0.77	-0.61	-0.99	-0.99	-0.71	-0.71	0.85	-0.42
Retained Earnings	-0.91	-0.82	0.79		-0.68	-0.7	-0.97	-0.89	0.23	-0.59	-0.76	-0.87	-0.92	0.61	-0.96	-0.9	-0.81	-0.79	-0.97	-0.97	0.81	-0.82
Accounts Payable	0.84	0.81	-0.91	-0.68		0.22	0.78	0.85	-0.16	0.51	0.8	0.41	0.72	-0.7	0.64	0.41	0.88	0.88	0.58	0.58	-0.89	0.35
Net Receivables	0.61	0.56	-0.44	-0.7	0.22		0.63	0.58	-0.11	-0.01	0.54	0.85	0.69	-0.41	0.81	0.84	0.42	0.46	0.78	0.78	-0.51	0.62
Total Liab	0.92	0.83	-0.84	-0.97	0.78	0.63		0.91	-0.21	0.67	0.79	0.85	0.92	-0.66	0.93	0.87	0.84	0.82	0.95	0.95	-0.88	0.76
Total Current Assets	1.0	0.98	-0.98	-0.89	0.85	0.58	0.91		-0.24	0.53	0.96	0.74	0.95	-0.64	0.87	0.74	0.97	0.97	0.82	0.82	-0.87	0.54
Common Stock	-0.24	-0.24	0.25	0.23	-0.16	-0.11	-0.21	-0.24		-0.16	-0.32	-0.21	-0.37	-0.34	-0.23	-0.21	-0.29	-0.3	-0.26	-0.26	0.36	-0.17
Short Term Debt	0.54	0.45	-0.51	-0.59	0.51	-0.01	0.67	0.53	-0.16		0.39	0.5	0.5	-0.33	0.41	0.52	0.57	0.47	0.55	0.55	-0.48	0.53
Net Tangible Assets	0.95	0.98	-0.97	-0.76	0.8	0.54	0.79	0.96	-0.32	0.39		0.63	0.93	-0.47	0.78	0.64	0.96	0.97	0.7	0.7	-0.79	0.39
Property Plant Equipment	0.77	0.68	-0.6	-0.87	0.41	0.85	0.85	0.74	-0.21	0.5	0.63		0.82	-0.5	0.86	0.99	0.62	0.6	0.92	0.92	-0.68	0.77
Capital Surpluse	0.96	0.92	-0.9	-0.92	0.72	0.69	0.92	0.95	-0.37	0.5	0.93	0.82		-0.46	0.93	0.84	0.91	0.91	0.9	0.9	-0.82	0.66
Long Term Investments	-0.63	-0.58	0.6	0.61	-0.7	-0.41	-0.66	-0.64	-0.34	-0.33	-0.47	-0.5	-0.46		-0.57	-0.47	-0.56	-0.56	-0.53	-0.53	0.67	-0.36
Current Deferred Revenue	0.88	0.8	-0.77	-0.96	0.64	0.81	0.93	0.87	-0.23	0.41	0.78	0.86	0.93	-0.57		0.89	0.76	0.77	0.97	0.97	-0.79	0.78
Short Long Term Debt	0.78	0.69	-0.61	-0.9	0.41	0.84	0.87	0.74	-0.21	0.52	0.64	0.99	0.84	-0.47	0.89		0.63	0.61	0.95	0.95	-0.66	0.81
Net Invested Capital	0.96	0.97	-0.99	-0.81	0.88	0.42	0.84	0.97	-0.29	0.57	0.96	0.62	0.91	-0.56	0.76	0.63		0.99	0.72	0.72	-0.83	0.47
Net Working Capital	0.96	0.97	-0.99	-0.79	0.88	0.46	0.82	0.97	-0.3	0.47	0.97	0.6	0.91	-0.56	0.77	0.61	0.99		0.7	0.7	-0.83	0.46
Long Term Debt	0.84	0.74	-0.71	-0.97	0.58	0.78	0.95	0.82	-0.26	0.55	0.7	0.92	0.9	-0.53	0.97	0.95	0.72	0.7		1.0	-0.77	0.85
Long Term Debt Total	0.84	0.74	-0.71	-0.97	0.58	0.78	0.95	0.82	-0.26	0.55	0.7	0.92	0.9	-0.53	0.97	0.95	0.72	0.7	1.0		-0.77	0.85
Capital Stock	-0.87	-0.81	0.85	0.81	-0.89	-0.51	-0.88	-0.87	0.36	-0.48	-0.79	-0.68	-0.82	0.67	-0.79	-0.66	-0.83	-0.83	-0.77	-0.77		-0.53
Deferred Long Term Liab	0.57	0.43	-0.42	-0.82	0.35	0.62	0.76	0.54	-0.17	0.53	0.39	0.77	0.66	-0.36	0.78	0.81	0.47	0.46	0.85	0.85	-0.53

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Arcturus Therapeutics

Gross Profit Over Time

According to the company disclosure, Arcturus Therapeutics Holdings reported 62.95 M of gross profit. This is 97.19% lower than that of the Biotechnology sector and 93.38% lower than that of the Health Care industry. The gross profit for all United States stocks is 99.77% higher than that of the company.

Arcturus Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcturus Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcturus Therapeutics could also be used in its relative valuation, which is a method of valuing Arcturus Therapeutics by comparing valuation metrics of similar companies.

Arcturus Therapeutics is currently under evaluation in gross profit category among its peers.

Arcturus Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcturus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcturus Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Arcturus Fundamentals

	Return On Equity	-0.23
	Return On Asset	-0.12
	Profit Margin	(0.39) %
	Operating Margin	(0.26) %
	Current Valuation	250.29 M
	Shares Outstanding	27.09 M
	Shares Owned By Insiders	8.45 %
	Shares Owned By Institutions	90.17 %
	Number Of Shares Shorted	4.58 M
	Price To Earning	119.50 X
	Price To Book	1.75 X
	Price To Sales	2.86 X
	Revenue	157.75 M
	Gross Profit	62.95 M
	EBITDA	(24.17 M)
	Net Income	(29.73 M)
	Cash And Equivalents	283.49 M
	Cash Per Share	10.67 X
	Total Debt	30.22 M
	Debt To Equity	0.58 %
	Current Ratio	3.14 X
	Book Value Per Share	9.67 X
	Cash Flow From Operations	(18.1 M)
	Short Ratio	14.82 X
	Earnings Per Share	(2.33) X
	Target Price	79.47
	Number Of Employees	180
	Beta	2.64
	Market Capitalization	458.05 M
	Total Asset	429.4 M
	Retained Earnings	(367.87 M)
	Working Capital	304.6 M
	Current Asset	54.55 M
	Current Liabilities	3.52 M
	Net Asset	429.4 M

About Arcturus Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arcturus Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcturus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcturus Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC